Principal Manufacturing Deal Finance Leader — Glass Acquisition Evidence

The mandate

An investment committee needs a defensible financial view of a proposed glass manufacturing acquisition whose earnings and working-capital claims depend on plant assumptions that require verification. The principal manufacturing deal finance leader will produce an evidence-based diligence pack, downside financial bridge and integration-control design. The work is bounded to financial analysis and transfer planning; it does not offer legal diligence assurance, technical furnace certification or responsibility for whether the transaction is completed.

Four months of work begin on 26 October 2026, with four days of weekly capacity reserved. The 4 December 2026 milestone is a reconciled earnings and working-capital evidence book. On 22 January 2027, the second milestone is a downside valuation-input and funding sensitivity pack. By 26 February 2027, the final output is the verified findings report and a practical finance integration-control blueprint for the agreed acquisition perimeter.

The group CFO and investment committee sponsor accept the deliverables jointly. Tests require traceability from every material adjustment to source evidence, reproducible sensitivities and clear treatment of missing or contradictory records. Internal specialists must rerun selected earnings and working-capital analyses and explain the integration-control priorities. Fee release is 30% for accepted evidence, 30% for sensitivities and 40% for final transfer; neither deal signing nor a favourable investment recommendation is an acceptance condition.

The sponsor supplies authorised data-room access, management accounts, inventory records, contracts and a five-person financial working group. Engineering, legal and tax advisers provide their own specialist conclusions. Seller negotiation, audit opinions and actual post-close system implementation are excluded. New target entities or additional operating sites require written change control, including revised samples and timing, so the independent financial conclusion does not become diluted by an unbounded transaction support request.

What you will own

• Reconcile the target's earnings evidence to underlying sales, cost and inventory records, distinguishing recurring performance from unsupported adjustments and documenting what cannot yet be verified within the authorised data perimeter.
• Test working-capital claims against ageing, settlement and stock evidence, identifying whether apparent normalisation assumptions conceal delayed obligations, slow-moving inventory or changes in commercial practice that would affect the buyer.
• Build downside financial sensitivities using specialist-supported plant inputs, showing the consequence of different yield, energy and capacity assumptions without representing the consultant's financial model as technical production assurance.
• Translate diligence findings into finance integration-control priorities, naming the evidence and internal owners required after completion while keeping legal claims and engineering remediation outside the financial workstream's authority.
• Produce an investment committee report that separates verified conclusion, qualified estimate and missing information, making clear which decision risks remain rather than forcing the findings toward a predetermined transaction recommendation.
• Validate final transfer by having internal specialists reproduce selected analyses and explain the proposed controls, recording residual limitations and versioned supporting files before the four-month engagement is accepted.

Candidate qualifications

• Be a Chartered Accountant with a 22–28-year finance career and meaningful manufacturing CFO, M&A or diligence responsibility. Show a transaction where your financial evidence changed an investment assumption or integration priority. The requirement is personal ownership of substantive findings, not association with a completed acquisition whose financial analysis was performed and defended by another adviser.
• Demonstrate manufacturing costing, inventory and earnings-quality judgement. Explain how you verified an adjustment, challenged working-capital normalisation and treated records that contradicted management's account. You must understand the boundary between financial sensitivity and engineering assurance, obtaining qualified plant inputs rather than using a plausible spreadsheet to imply that technical performance has been independently validated.
• Have delivered decision-ready diligence to senior forums with balanced treatment of uncertainty. Evidence should show how you resisted sponsor or seller pressure, preserved traceability and distinguished an investment concern from an accounting difference. A credible consultant can produce a useful qualified conclusion when data is incomplete and does not promise certainty or transaction success beyond the accepted scope.
• Reserve four days weekly through the stated calendar, including target-site evidence reviews. Bring reproducible workpapers, confidential information controls and practical transfer experience. The final integration blueprint must be usable by internal finance without continuing personal explanation, and any additional target perimeter must be identified through change control before it disrupts the originally agreed acceptance and delivery obligations.

Application

Applications for this mandate are received in one way only: through the India Board Terminal's application process. It is automated end to end. Your Executive Passport travels to the mandate holder in its confidential form, your answers to the three questions below are read before anything else in your file, and every stage that follows is recorded on your applications page.

There is no address to write to and no intermediary to call. The mandate holder reads what the Terminal delivers and nothing else, which is what keeps the process the same for every applicant and keeps your name out of it until you release it. Applications close on 10 October 2026. Mandate reference CVU-CON-2026-IND-115.